The AJMC® Immuno-Oncology compendium is a comprehensive resource for clinical news and expert insights for treatments that utilize the body's immune system to fight cancer, such as immune checkpoint inhibitors and chimeric antigen receptor T-cell therapies.
May 17th 2024
The FDA has approved tarlatamab (Imdelltra; Amgen), a novel bispecific T-cell engager, to treat patients with extensive-stage small cell lung cancer (SCLC).
Impact of COVID-19 on Disparities in Cancer Outcome Spans Various Groups of Patients
August 13th 2021Recent research showed that patients with Medicaid are more likely than commercially insured patients to have worsened end-of-life experience and that Black patients with breast cancer fare worse than other ethnic groups when it comes COVID-19 outcomes.
Read More
Researchers Highlight Delivery of CAR T-Cell Therapy Through Modified AAV
August 11th 2021In a preclinical study, researchers were able to show that their modified adeno-associated virus (AAV) vector safely delivered the chimeric antigen receptor (CAR) gene into the host cells and produced enough CAR T cells to cause effective tumor regression and elicit antitumor immunological characteristics in a mouse model of human T-cell leukemia.
Read More
MHC-II May Be Predictor of Immunotherapy Response in HR+, Triple-Negative Breast Cancers
August 6th 2021The study, according to the researchers, is the first to demonstrate the potential use of major histocompatibility complex class II (MHC-II) expression as a predictor of immunotherapy response in these patients.
Read More
ACCC Survey Reveals Biggest Challenges and Concerns Regarding IO Therapies
August 4th 2021The Association of Community Cancer Centers’ (ACCC’s) annual survey on immuno-oncology (IO) therapies highlighted major concerns among health care providers regarding financial impacts, education, and access to clinical trial data.
Read More
Immunotherapy Tops Chemotherapy for Improving Outcomes in Real-World Study of Merkel Cell Carcinoma
July 23rd 2021Compared with chemotherapy, patients receiving avelumab or another immunotherapy had higher response rates and higher rates of survival in locally advanced Merkel cell carcinoma (laMCC) and metastatic Merkel cell carcinoma (mMCC).
Read More
Researchers Outline Ongoing Studies, Challenges of CAR T-Cell Therapy in GBM
July 16th 2021Although there is hope chimeric antigen receptor (CAR) T-cell therapy can revolutionize how to treat glioblastoma multiforme (GBM), there is still more research to be done, say investigators, noting that research on CAR T-cell therapy in this setting is still in early stages.
Read More
Pooled Results From Atezolizumab Trials Show Immune-Related AEs Can Predict Longer OS
July 5th 2021Data from IMpower 130, IMpower 132, and IMpower 150 confirm that combining atezolizumab with chemotherapy is the best first-line treatment in advanced NSCLC when anti-PD-L1 therapy is indicated.
Read More
Longer-Term Data Show Yescarta Reduces Mortality vs Other Therapies for FL
June 24th 2021Yescarta, the first and only approved chimeric antigen receptor T-cell therapy for these patients, was shown to achieve durable responses in a majority of patients and reduced the risk of death compared with other treatments.
Read More
Preclinical Models Suggest Promise of CAR-NK Cell Treatment in Several Solid Tumors
June 14th 2021Previous research has suggested the efficacy of chimeric antigen receptor natural killer (CAR-NK) cells in hematological malignancies, and more recently, preclinical findings have raised the question of whether the type of treatment could be a viable, potentially more attractive option for solid tumors.
Read More
Larry D. Anderson Jr, MD, PhD, associate professor, Harold C. Simmons Comprehensive Cancer Center, discusses updated findings of the phase II KarMMa trial assessing ide-cel chimeric antigen receptor (CAR) T-cell therapy for treatment of adult patients with relapsed or refractory multiple myeloma after 4 or more prior lines of therapy.
Watch
Camille Hertzka Addresses 5-Year PACIFIC Trial Findings, Future Ambitions for Durvalumab
June 7th 2021Camille Hertzka, vice president and head of Oncology, US Medical, AstraZeneca, discussed updated findings of the PACIFIC trial that indicated a third of patients with unresectable non-small cell lung cancer are stable at 5 years.
Watch
“Practice-Changing” Results Seen for Pembrolizumab in Adjuvant Setting in Renal Cell Carcinoma
June 7th 2021The study's lead author said researchers have searched for a generation for an effective therapy to give to high-risk patients with renal cell carcinoma after initial surgery for the tumor.
Read More
Kirk Shepard, MD, chief medical officer, senior vice president, and head of Global Medical Affairs, Eisai, discusses findings of a study showcasing similar health-related quality of life (HRQOL) scores between lenvatinib/pembrolizumab vs chemotherapy in patients with advanced endometrial carcinoma.
Watch
Robert Iannone, MD, MSCE, executive vice president of research and development for Jazz Pharmaceuticals, addresses findings of an abstract presented at ASCO 2021 which showed preliminary efficacy of lurbinectedin in combination with irinotecan in patients with advanced endometrial carcinoma.
Watch
Researchers Outline Potential Strategies for Overcoming CAR T Therapy Challenges
May 8th 2021Strategies for improving outcomes across hematologic cancers and solid tumors range from addressing cytokine release syndrome and neurotoxicity mediators, immune rejection, on-target off-tumor toxicity, post-infusion control limitation, and immunosuppressive tumor microenvironment.
Read More